AJPH
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

AJPH First Look, published online ahead of print Feb 28, 2007
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
AJPH.2006.087262v1
97/4/750    most recent
Right arrow Submit a response
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kurdyak, P. A.
Right arrow Articles by Mamdani, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kurdyak, P. A.
Right arrow Articles by Mamdani, M. M.
©
American Journal of Public Health, 10.2105/AJPH.2006.087262

Research and Practice

The Effect of Antidepressant Warnings on Prescribing Trends in Ontario, Canada

Paul A. Kurdyak 1*, David N. Juurlink 2, Muhammad M. Mamdani 2

1 Centre for Addiction and Mental Health
2 Institute for Clinical Evaluative Sciences

* To whom correspondence should be addressed. E-mail: paul_kurdyak{at}camh.net.


  Abstract

Objectives. We studied whether 5 regulatory agency advisories about the possible increased risk of suicidal behavior during antidepressant therapy had an effect on antidepressant prescription trends in Ontario. Methods. We conducted a population-based, time-series analysis of new monthly antidepressant prescriptions dispensed by the Ontario Drug Benefits program in 3 age groups (younger than 20 years, 20-65 years old, and older than 65 years) over a 7-year period (April 1998 to March 2005). The impact of five advisories about the possible risk of suicide during antidepressant therapy was also analyzed. Results. The number of new prescriptions for selective serotonin reuptake inhibitors as a group did not change after any antidepressant warning in any age group. However, the rate of new paroxetine prescriptions in patients younger than 20 years declined by 54% immediately after the first warning for paroxetine was issued in the United Kingdom in June 2003. That same warning had no effect on new paroxetine prescriptions in the other age categories. Conclusion. The warning about paroxetine use in depressed patients younger than 18 years that was issued in the United Kingdom led to a significant decrease in new paroxetine prescriptions for young patients in this country. By contrast, warnings in North America did not influence new antidepressant prescription rates in any patient group.

Key Words: Health Policy, Mental Health




This article has been cited by other articles:


Home page
 CMAJHome page
L. Y. Katz MD, A. L. Kozyrskyj PhD, H. J. Prior MSc, M. W. Enns MD, B. J. Cox PhD, and J. Sareen MD
Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults
Can. Med. Assoc. J., April 8, 2008; 178(8): 1005 - 1011.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
M. M. Mamdani PharmD MPH
Health advisories: when good intentions go bad
Can. Med. Assoc. J., April 8, 2008; 178(8): 1025 - 1026.
[Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
M. Olfson, S. C. Marcus, and B. G. Druss
Effects of Food and Drug Administration Warnings on Antidepressant Use in a National Sample
Arch Gen Psychiatry, January 1, 2008; 65(1): 94 - 101.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2007 by the American Public Health Association